Figure 1
From: A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
PK analysis of enrolled patient population: a relationship between plasma concentration vs time profiles for each (A) S-1 and (B) eribulin dose level.
Figure 1 | British Journal of Cancer
